|
|
|
|
gallium nitrate
A drug that lowers blood calcium. Used as treatment for hypercalcemia (too much calcium in the blood) and for cancer that has spread to the bone (bone metastases). (National Cancer Institute)
Chronic Myelocytic Leukemia - Genta Obtains Orphan Drug ... Mar 15, 2005
The leading drug in Genta's small molecule program is Ganite( R ) ( gallium nitrate injection ), which the Company is exclusively marketing in the US for ... I-Newswire.com (press release)
Genta Incorporated Announces Fourth Quarter and Year End 2004 ... Feb 17, 2005
...of the acceleration in the recognition of deferred revenues was partially offset by a reserve for potential returns of Ganite(R) (gallium nitrate injection). ... Yahoo News (press release)
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
Genta Announces Restructuring to Focus on Genasense(TM) Programs May 13, 2004
...sales employees. The Company also will cease actively marketing Ganite(R) (gallium nitrate injection), its only marketed product. In ... PR Newswire (press release) - May 13, 2004
... sales employees. The Company also will cease actively marketing Ganite(R) (gallium nitrate injection), its only marketed product. In ...
Genta Announces Restructuring to Focus on Genasense(TM) ProgramsYahoo News (press release) - May 13, 2004
... sales employees. The Company also will cease actively marketing Ganite® (gallium nitrate injection), its only marketed product. In ...
Genta Slashes Work Force To Curb Spending, Conserve CashBioWorld Online (subscription) - May 13, 2004
... employees. In the process, Genta is halting all active promotion of its only marketed product, Ganite (gallium nitrate injection). ...
Genta shares hit after drug application withdrawnInvestor's Business Daily (subscription) - May 13, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
GENTA WITHDRAWS GENASENSE MELANOMA NDA; REDUCES WORKFORCEPharmexec (press release) - May 13, 2004
... The company added that it will cease actively marketing its only marketed therapy, Ganite (gallium nitrate injection), indicated to treat cancer-related ...
NDA Withdrawn, But Genta's Genasense Work To ContinueBioWorld Online (subscription) - May 14, 2004
... Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ...
Genta downgraded after it withdraws drug applicationInvestor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta Announces Restructuring to Focus on Genasense(TM) Programs May 13, 2004
...sales employees. The Company also will cease actively marketing Ganite® (gallium nitrate injection), its only marketed product. In ... Yahoo News (press release) - May 13, 2004
... sales employees. The Company also will cease actively marketing Ganite® (gallium nitrate injection), its only marketed product. In ...
Genta Slashes Work Force To Curb Spending, Conserve CashBioWorld Online (subscription) - May 13, 2004
... employees. In the process, Genta is halting all active promotion of its only marketed product, Ganite (gallium nitrate injection). ...
Genta shares hit after drug application withdrawnInvestor's Business Daily (subscription) - May 13, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
GENTA WITHDRAWS GENASENSE MELANOMA NDA; REDUCES WORKFORCEPharmexec (press release) - May 13, 2004
... The company added that it will cease actively marketing its only marketed therapy, Ganite (gallium nitrate injection), indicated to treat cancer-related ...
NDA Withdrawn, But Genta's Genasense Work To ContinueBioWorld Online (subscription) - May 14, 2004
... Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ...
Genta downgraded after it withdraws drug applicationInvestor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta Slashes Work Force To Curb Spending, Conserve Cash May 13, 2004
...employees. In the process, Genta is halting all active promotion of its only marketed product, Ganite (gallium nitrate injection). ... BioWorld Online (subscription) - May 13, 2004
... employees. In the process, Genta is halting all active promotion of its only marketed product, Ganite (gallium nitrate injection). ...
Genta shares hit after drug application withdrawnInvestor's Business Daily (subscription) - May 13, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
GENTA WITHDRAWS GENASENSE MELANOMA NDA; REDUCES WORKFORCEPharmexec (press release) - May 13, 2004
... The company added that it will cease actively marketing its only marketed therapy, Ganite (gallium nitrate injection), indicated to treat cancer-related ...
NDA Withdrawn, But Genta's Genasense Work To ContinueBioWorld Online (subscription) - May 14, 2004
... Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ...
Genta downgraded after it withdraws drug applicationInvestor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta shares hit after drug application withdrawn May 13, 2004
The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ... Investor's Business Daily (subscription) - May 13, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
GENTA WITHDRAWS GENASENSE MELANOMA NDA; REDUCES WORKFORCEPharmexec (press release) - May 13, 2004
... The company added that it will cease actively marketing its only marketed therapy, Ganite (gallium nitrate injection), indicated to treat cancer-related ...
NDA Withdrawn, But Genta's Genasense Work To ContinueBioWorld Online (subscription) - May 14, 2004
... Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ...
Genta downgraded after it withdraws drug applicationInvestor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
GENTA WITHDRAWS GENASENSE MELANOMA NDA; REDUCES WORKFORCE May 13, 2004
The company added that it will cease actively marketing its only marketed therapy, Ganite (gallium nitrate injection), indicated to treat cancer-related ... Pharmexec (press release) - May 13, 2004
... The company added that it will cease actively marketing its only marketed therapy, Ganite (gallium nitrate injection), indicated to treat cancer-related ...
NDA Withdrawn, But Genta's Genasense Work To ContinueBioWorld Online (subscription) - May 14, 2004
... Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ...
Genta downgraded after it withdraws drug applicationInvestor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
NDA Withdrawn, But Genta's Genasense Work To Continue May 14, 2004
Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ... BioWorld Online (subscription) - May 14, 2004
... Meanwhile, the company has decided to quit promoting its only marketed product, Ganite (gallium nitrate), an injected therapy for cancer-related hypercalcemia ...
Genta downgraded after it withdraws drug applicationInvestor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta downgraded after it withdraws drug application May 14, 2004
The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ... Investor's Business Daily (subscription) - May 14, 2004
... The company said it would cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only existing ...
Genta pushes biotech stocks lowerInvestor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta pushes biotech stocks lower May 14, 2004
21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ... Investor's Business Daily (subscription) - May 14, 2004
... 21 cents, or 4 percent, to $4.68 one day after the company moved to cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite ...
Drug stocks end lower as Genta falls 7 percentInvestor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Drug stocks end lower as Genta falls 7 percent May 14, 2004
On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ... Investor's Business Daily (subscription) - May 14, 2004
... On Thursday, the company also said it would cut jobs and stop trying to sell its only marketed product, gallium nitrate injection Ganite. ...
Drug stocks end lower after Pfizer settlementInvestor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Drug stocks end lower after Pfizer settlement May 13, 2004
The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ... Investor's Business Daily (subscription) - May 13, 2004
... The company said it will cut 85 jobs, or about 45 percent of its work force, and will stop marketing the gallium nitrate injection Ganite, its only marketed ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsYahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta Announces 1st Quarter 2004 Financial Results and Highlights Apr 29, 2004
Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ... Yahoo News (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite® (gallium nitrate injection). "Genta ...
Genta Announces 1st Quarter 2004 Financial Results and HighlightsPR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
Genta Announces 1st Quarter 2004 Financial Results and Highlights Apr 29, 2004
Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ... PR Newswire (press release) - Apr 29, 2004
... Officer. The Company also commented upon the introduction of its first marketed product, Ganite(R) (gallium nitrate injection). ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... May 3, 2004
The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ... PR Newswire (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced ... May 3, 2004
The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ... Yahoo News (press release) - May 3, 2004
... The leading drug in Genta's Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ...
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... Medical News Today
FDA Advisory Committee Reviews Genasense ™ For Use in Advanced ... May 4, 2004
The leading drug in Genta’s Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the US for treatment ... Medical News Today
Resources from the National Cancer Institute on gallium nitrate:
|
|
|
